ANDA 214732, held by Novast Labs. Cyclobenzaprine Hydrochloride.
As of Nov 16, 2026, ANDA 214732 (Cyclobenzaprine Hydrochloride), held by Novast Labs, was first approved by FDA on Aug 27, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 27, 2024 | Original application | Approved | None posted |
| Cyclobenzaprine Hydrochloride15MG · capsule, extended release;oral | Cyclobenzaprine Hydrochloride | Rx |
| Cyclobenzaprine Hydrochloride30MG · capsule, extended release;oral | Cyclobenzaprine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters